Alector (ALEC) vs Invivyd (IVVD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alector (ALEC) has outperformed Invivyd (IVVD) over the past year, losing 34.4% versus a loss of 57.3%. Over five years, ALEC leads with a -91.3% price change compared with -97.8% for IVVD. Alector is the larger company by market cap ($225.5 million vs $206.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | IVVD |
|---|---|---|
| Share price | $2.02 | $0.7004 |
| Market cap | $225.55M | $206.45M |
| 1-day change | +5.21% | -3.87% |
| YTD return | +29.49% | -71.64% |
| 1-year return | -34.42% | -57.29% |
| 5-year return | -91.33% | -97.84% |
| EPS (TTM) | $-1.09 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $3.07 |
| 52-week low | $1.09 | $0.528 |
| Distance from 52-week high | -40.59% | -77.19% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +63.37% | +1327.76% |
| Average volume | 2.86M | 4.78M |
| Shares outstanding | 111.66M | 294.76M |
| Employees | 103 | 122 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALEC has outperformed IVVD by 22.9 percentage points over the past year.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
ALEC vs IVVD FAQ
Which is bigger, Alector or Invivyd?
Alector (ALEC) is larger, with a market capitalization of $225.55M compared with $206.45M for Invivyd (IVVD).
Which stock has performed better over the past year, ALEC or IVVD?
ALEC returned -34.42% over the past 12 months, compared with -57.29% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Invivyd in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.